Understanding the risk factors that give rise to human disease is essential to early detection and development of effective treatments for disease prevention. Human disease risk represents an interaction between underlying genetic predisposition, which is largely set from the moment of conception, and the varied and changing exposures that occur over an individual’s lifetime, including… Continue reading Mapping Metabolic Changes for Diabetes Prediction with Machine Learning
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. To achieve the statistical power for robust discovery of biological insight, we often need to perform multi-omics data integration that combines different omics layers – including high dimensional metabolomics, proteomics, genomics, and… Continue reading Experts On… Multi-Omics Data Integration
There are tens of thousands of unknown molecules circulating in human blood – thousands of which could represent robust biomarkers. Sapient uses our next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to provide nontargeted metabolomics services, rapidly measuring >15,000 small molecule biomarkers per biosample to identify key molecules of interest – including yet-unmapped chemistries. We then… Continue reading Chemistries & Methods: How We Achieve Breadth and Depth in Chemical Discovery
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. How can machine learning (ML) be used to boost biomarker discovery potential? Sapient’s Co-Founder and Head of Computational R&D Operations, Dr. Saumya Tiwari, shares how we leverage ML in data pre-processing as… Continue reading Experts On… Machine Learning in Biomarker Discovery
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. What does an engagement with Sapient look like? Hear from Dr. Tanya Nguyen, Sapient’s Head of Operations, as she explains how her team approaches new discovery projects with sponsors and research partners.… Continue reading Experts On… Approaching Experimental Design
CNS diseases can have a wide range of symptoms which can make them difficult to diagnose and treat based on clinical presentation alone. Biomarkers can provide objective measures of the underlying disease process, which can help to distinguish between different subtypes of the disorder so that targeted therapies can be aligned with the right patients.… Continue reading Thinking outside the brain to advance CNS drug development
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. In this segment, Sapient’s Co-Founder and Head of Data Science, Dr. Tao Long, shares how our data science team goes about determining the optimal biocomputational approaches for new sponsor studies. Dr. Long… Continue reading Experts On… Defining Biocomputational Approaches
Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human lipidome at a rate that is unmatched for discovery, providing a means to more rapidly elucidate lipid function and uncover previously unknown lipid biomarkers that associate with early disease, disease progression, and drug response. By enabling sponsors rapidly identify, validate, and translate… Continue reading Untargeted Lipidomics Services for an Unprecedented Scale of Biomarker Discovery
Now On Demand | Hosted by Fierce Pharma Watch Now In this session, Sapient discusses application of its next-generation mass spectrometry approaches for large-scale biomarker discovery across diverse human diseases, enabling measure of tens of thousands of small molecule biomarkers across tens of thousands of individuals. See how integration of these biomarker studies with human genetics… Continue reading Fierce Webinar: Population-Scale Circulating Biomarker Discovery to Accelerate Drug Development
Disease processes are complex. Individuals with the same genetic disorder, symptoms, and/or diagnosis can have varied prognosis and response to treatment. The mechanisms underlying disease can be quite different and may be influenced by a range of internal and external exposures experienced over time. Sensitive and specific biomarkers allow us to stratify patients by these biological… Continue reading Be More Specific: Solving the Specificity Challenge in Metabolomics
